Research

Hormonal

In Type 1 Diabetes, hyperglucagonemia (excess glucagon) is the primary cause of hyperglycemia and catabolic symptoms, rather than insulin deficiency alone.

For Type 1 Diabetics, managing blood sugar requires addressing high glucagon levels, not just injecting more insulin. Current insulin monotherapy often fails to suppress glucagon without causing hypoglycemia elsewhere. Therapies that suppress glucagon (like somatostatin analogs or leptin) may offer better stability than insulin alone.

GoodSupportsHIGH confidence
Here we propose that glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes.
Roger H. Unger et al. · Journal of Clinical Investigation · 2012

Why this rating

Strong mechanistic evidence from animal models (Gcgr-null mice, dogs) and human clamp studies, though human clinical trials for long-term glucagon suppression are noted as lacking.

Source

Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover

Roger H. Unger et al. · Journal of Clinical Investigation · 2012

DOI 10.1172/jci60016

narrative_reviewCited 667×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →